Table 1 Characteristics of older adults newly prescribed and not prescribed ezetimibe within six months of a hospital discharge for an AMI
|  | No Ezetimibe Prescription N = 69, 895 | New Ezetimibe Prescription N = 1230 | Standardized Difference | ||
|---|---|---|---|---|---|
Age | N | % | N | % | Â |
Mean (SD) | 78.42 | 7.72 | 74.84 | 6.43 | 50% |
Median (IQR) | 78 | (72–84) | 74 | (69–79) |  |
Female | 31, 995 | 45.8% | 559 | 45.4% | 1% |
Rural location | 11, 497 | 16.4% | 224 | 18.2% | 5% |
Income quintile | |||||
 1 (lowest) | 15, 454 | 22.1% | 243 | 19.8% | 6% |
 2 | 14, 762 | 21.1% | 253 | 20.6% | 1% |
 3 | 14, 028 | 20.1% | 257 | 20.9% | 2% |
 4 | 13, 162 | 18.8% | 256 | 20.8% | 5% |
 5 (highest) | 12, 489 | 17.9% | 221 | 18.0% | 0% |
Long-term care | 3587 | 5.1% | < 6 | < 0.5% | – |
Year of hospital discharge | |||||
 2005 | 8390 | 12.0% | 131 | 10.7% | 4% |
 2006 | 7678 | 11.0% | 174 | 14.1% | 10% |
 2007 | 7974 | 11.4% | 187 | 15.2% | 11% |
 2008 | 7786 | 11.1% | 121 | 9.8% | 4% |
 2009 | 7537 | 10.8% | 114 | 9.3% | 5% |
 2010 | 7585 | 10.9% | 127 | 10.3% | 2% |
 2011 | 7530 | 10.8% | 148 | 12.0% | 4% |
 2012 | 7572 | 10.8% | 117 | 9.5% | 4% |
 2013 | 7843 | 11.2% | 111 | 9.0% | 7% |
Rostered to a family physician | 55, 396 | 79.3% | 1015 | 82.5% | 8% |
Comorbiditiesa | |||||
Coronary artery disease | 27, 838 | 39.8% | 509 | 41.4% | 3% |
Stroke/Transient ischemic attack | 3012 | 4.3% | 40 | 3.3% | 5% |
Diabetes | 64, 973 | 93.0% | 1102 | 89.6% | 12% |
Peripheral vascular disease | 2199 | 3.1% | 36 | 2.9% | 1% |
Chronic kidney disease | 8809 | 12.6% | 123 | 10.0% | 8% |
Dialysis | 1080 | 1.5% | 10 | 0.8% | 7% |
Hypertension | 64, 745 | 92.6% | 1094 | 88.9% | 13% |
Liver disease | 1905 | 2.7% | 32 | 2.6% | 1% |
Congestive heart failure | 14, 634 | 20.9% | 146 | 11.9% | 24% |
Coronary revascularization | 2555 | 3.7% | 71 | 5.8% | 10% |
Charlson comorbidity index | |||||
 0 (no hospitalizations) | 46, 300 | 66.2% | 921 | 74.9% | 19% |
 1 | 7498 | 10.7% | 114 | 9.3% | 5% |
 2 | 6248 | 8.9% | 95 | 7.7% | 4% |
 3 or higher | 9849 | 14.1% | 100 | 8.1% | 19% |
Healthcare Utilizationb | |||||
Visit to a family physician | 66, 325 | 94.9% | 1165 | 94.7% | 1% |
Visit to cardiologist | 32, 321 | 46.2% | 559 | 45.4% | 2% |
Visit to endocrinologist | 5025 | 7.2% | 106 | 8.6% | 5% |
Visit to internist | 24, 020 | 34.4% | 393 | 32.0% | 5% |
Evidence of at least 1 cholesterol test | 35, 060 | 50.2% | 797 | 64.8% | 30% |
Baseline medicationsc | |||||
Any statin | 30, 329 | 43.4% | 556 | 45.2% | 4% |
Statin intensityd | |||||
 Low | 2335 | 3.3% | 29 | 2.4% | 5% |
 Moderate | 20, 626 | 29.5% | 314 | 25.5% | 9% |
 High | 6857 | 9.8% | 205 | 16.7% | 20% |
 Other | 511 | 0.7% | 8 | 0.7% | 0% |
Fibrates | 1430 | 2.0% | 56 | 4.6% | 15% |
Thienopyridines | 1576 | 2.3% | 21 | 1.7% | 4% |
Beta-blocker | 24, 614 | 35.2% | 438 | 35.6% | 1% |
Angiotensin converting enzyme inhibitor | 25, 701 | 36.8% | 415 | 33.7% | 6% |
Angiotensin receptor blocker | 14, 131 | 20.2% | 303 | 24.6% | 11% |